Platinum’s Ogden backs COVID-19 vaccine creators

healthcare/covid-19/vaccine/Pfizer/Platinum/BioNTech/

20 November 2020
| By Laura Dew |
image
image
expand image

Platinum International Health Care manager Bianca Ogden is well placed to benefit from the COVID-19 vaccine trials as her fund holds both leading players.

It was announced this week that US drug firm Moderna had created a vaccine with 94% effectiveness while Pfizer had a successful trial, in partnership with German biotech firm BioNTech, with 90% effectiveness earlier this month.

Ogden held 2.1% in BioNTech, the fund participated in its pre-IPO back in mid-2019, as well as smaller amounts in Moderna and a third biotech firm called Curevac.

Speaking to Money Management, she said: “We have done work on mRNA as a therapeutic and vaccine for a couple of years and had a belief that both Moderna and BioNTech had the right expertise to progress their programs. BioNTech, in particular, also develops other drug modalities to comprehensively treat cancer.

“We visited both companies, met with their teams and felt this technology has legs and could have wide-ranging consequences for the vaccine industry as well as in therapeutics. Both companies were well funded and had partners to share the load.”

She said the trial results of 90% for Pfizer & BioNTech and 94% for Moderna were “great to see” but she would wait to see how durable was the response.

“It is great to see these mRNA vaccines emerging rapidly and in the end the world will need various vaccines to satisfy demand,” Ogden said.

The Platinum International Health Care fund returned 24.9% over one year to 31 October, 2020, according to FE Analytics, versus average returns by the specialist sector within the Australian Core Strategies universe of 11.2%.

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

So we are now underwriting criminal scams?...

2 months 2 weeks ago

Glad to see the back of you Steve. You made financial more expensive, not more affordable as you claim, and presided ...

2 months 3 weeks ago

Completely agree Peter. The definition of 'significant change is circumstances relevant to the scope of the advice' is s...

4 months 3 weeks ago

ASIC has suspended the Australian Financial Services Licence of a Melbourne-based financial advice firm....

1 week 1 day ago

The corporate regulator has issued infringement notices to three AFSLs whose financial advisers provided personal advice to a retail client while unregistered....

1 week 6 days ago

ASIC has released the results of its first adviser exam to be held in 2025, with 241 candidates attempting the test....

2 weeks 4 days ago

TOP PERFORMING FUNDS

ACS FIXED INT - AUSTRALIA/GLOBAL BOND